By Marie Rosenthal, MS
The FDA approved bictegravir-emtricitabine-tenofovir alafenamide (BIC/FTC/TAF), a once-daily, single-tablet regimen for the treatment of HIV-1 infection, but the product will carry a boxed warning about hepatitis B virus infection.
BIC/FTC/TAF (Biktarvy, Gilead Sciences) combines the novel, unboosted integrase strand transfer inhibitor (INSTI) bictegravir with the demonstrated safety and efficacy of FTC/TAF (Descovy, Gilead Sciences), a dual nucleoside reverse transcriptase